• News
  • Money

Juno Therapeutics (JUNO) Rating Reiterated by Raymond James Financial

Juno Therapeutics (JUNO) Rating Reiterated by Raymond James Financial

Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Rhumbline Advisers stated it has 0.01% of its portfolio in Juno Therapeutics, Inc.

Several hedge funds and other institutional investors have recently made changes to their positions in JUNO.

When we see the company's Volatility, it now has a monthly volatility of 4.89% and weekly volatility of 6.20%.

With all other things going on, Juno Therapeutics, Inc. The firm has a market capitalization of $8,148.52, a P/E ratio of -20.06 and a beta of 2.32. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.07. The business had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million.

Juno Therapeutics Inc. (NASDAQ:JUNO) gross margin percentage stands at 0% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent. Juno Therapeutics's quarterly revenue was up 96.9% compared to the same quarter past year. During the same quarter in the previous year, the company posted ($0.57) earnings per share. In a report released today, Guggenheim analyst Anthony Butler downgraded JUNO to Hold.

Syed maintains a Buy rating on Celgene shares with a price target of $128. Zacks Investment Research lowered shares of Juno Therapeutics from a hold rating to a sell rating in a research note on Tuesday, November 7th. Finally, JPMorgan Chase & Co. reissued a hold rating on shares of Juno Therapeutics in a research note on Thursday, January 11th. On average, equities analysts forecast that Juno Therapeutics, Inc. will post ($2.98) earnings per share for the current year. Finally, Wedbush reiterated an "outperform" rating and set a $64.00 target price (up previously from $42.00) on shares of Juno Therapeutics in a research report on Thursday, November 2nd. "Ultimately, through all this investigation into the company's performance the analyst decides whether their stock is a "buy", sell" or hold". (JUNO)'s current share price. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company's stock valued at $96,742,000 after purchasing an additional 222,754 shares during the last quarter. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard Klausner sold 12,724 shares of the stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $44.76, for a total transaction of $1,611,360.00. The disclosure for this sale can be found here.

TRADEMARK VIOLATION WARNING: This report was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes.

Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ for $105 per share in cash, representing an equity value of approximately $11.6 billion (on a fully diluted basis).

Juno is a pioneer in the development of vehicle (chimeric antigen receptor) T and TCR (T cell receptor) therapeutics with a broad, novel portfolio evaluating multiple targets and cancer indications.

Leave Your Comment

Leave Your Comment

Latest News

Breaking News


Hernandez proves his worth to Hammers in draw with Bournemouth

Javier Hern√°ndez is close to completing a quick fire exit from West Ham according to reports today. Ryan Fraser put Bournemouth ahead with an angled finish on 71 minutes.

Jos Buttler inspires England to ODI series win over Australia

Morgan praised the England bowlers and hoped that they will be able to continue in the same vein over the rest of the series. With the series now wrapped up 3-0, it seems unlikely the 32-year-old will return for the visitors in the next week.

Sanchez Undergoing Manchester United Medical Now, Unveiling 'Likely On Tuesday'

Sanchez, 29, is out of contract in June and is thought to have agreed personal terms with the Old Trafford club. There are also pictures of him in the back seat of a vehicle heading to United's Carrington training complex.

Celgene's (CELG) "Hold" Rating Reiterated at Piper Jaffray Companies

According to their observations and findings, the stock could provide a high EPS of $2.04/share and a low EPS of $1.86/share. The biopharmaceutical company reported $1.91 EPS for the quarter, beating analysts' consensus estimates of $1.87 by $0.04.

Carillion collapse could lead to thousands of job losses in UK

Carillion, with about 20,000 employees in Britain, touched myriad sectors of British life, as well as operating overseas. Its failure means the government will have to provide funding to maintain the public services run by Carillion.

Las Vegas Shooting Mystery Continues

He had lost a "significant amount of wealth" since September 2015, which led to "bouts of depression", the sheriff has said. This week, officials also announced no charges are expected against Paddock's girlfriend, Marilou Danley.

Australian Open: Hyeon Chung Knocks Out Alexander Zverev In Five Sets

And the bottom half of the draw lost another seed when Tomas Berdych strolled past Del Potro in a surprisingly comfortable win. Alexander Zverev of Germany waves as he leaves after losing against Chung Hyeon of South Korea.

Winter storm expected to hit Nebraska, parts of Iowa, Kansas

After highs on in the 30's on Sunday, we'll be in the upper 30's and 40's for the first part of the week with dry skies. Communities around Rochester could see around.04 inches of ice on the ground before the snow starts falling.

'Serial stowaway' arrested again after flying to London, police say

Judge Stephanie K Miller said: "There is no pun intended for your client, but she is a flight risk given the number of offences". In a statement, the TSA said they are "working closely with our law enforcement and airline partners in that effort".

Samsung starts mass production of 'industry's first' 16Gb GDDR6 memory

It comes in a 16Gb density, double that of its 20nm 8Gb GDDR5 memory, which runs at 1.55V and is found in modern graphics cards. We should also mention the 18-gigabits-per-second (Gbps) pin speed and data transfers of 72 gigabytes per second (Gbps).